Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan NEW YORK and MELBOURNE, Australia, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine...

ARUP Laboratories and The Children's Hospital of Philadelphia Form Partnership to Offer High-resolution HLA genotyping by Next Generation Sequencing SALT LAKE CITY, Oct. 8, 2014 (GLOBE NEWSWIRE) -- ARUP Laboratories announced today that they will be offering high-resolution HLA genotyping by next generation sequencing (NGS) under an agreement with...

Mesoblast Provides Update on Clinical Programs of Prochymal for Crohn's Disease and Acute Graft Versus Host Disease NEW YORK and MELBOURNE, Australia, April 28, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided an update on its clinical programs using the...

Mesoblast Reports Strong Half-Year Financial Results NEW YORK and MELBOURNE, Australia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and...

IMPROVED SURVIVAL IN CHILDREN WITH LIFE THREATENING GRAFT VERSUS HOST DISEASE REPORTED AFTER TREATMENT WITH MESOBLAST'S CELL THERAPY NEW YORK and MELBOURNE, Australia, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that a peer-reviewed article in the...